EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), has historically played a key role in the EXTREME regimen (cetuximab + platinum + 5-fluorouracil), which was considered the first-line standard of care for recurrent/metastatic (R/M) HNSCC prior to the introduction of immunotherapy (Vasiliadou et al., 2021).